Ffr-gUidance for compLete non-cuLprit REVASCularization. A Registry Randomized Clinical Trial.
FULL REVASC will randomize 4052 patients with STEMI or high-risk NSTEMI, and multivessel disease, after primary PCI of the culprit lesion has been done. The treatment arms are
- ”Full revascularisation” with FFR-guided PCI of all vessels of at least 2,5 mm diameter. The PCI should be completed within the index admission.
- ”Initial conservative” with PCI of the culprit lesion only during index admission.
The primary endpoint is mortality and myocardial infarction after minimum one year follow-up. Key secondary endpoint is unplanned revascularization during follow-up.
The patients will be followed up by telephone interview after 30 days and one year. Data from healthcare registries will be used in countries where they are available.
The study will include a large number of PCI-centers in the Nordic countries, Latvia, Poland and possibly other countries. It is anticipated that the results will influence treatment guidelines globally. The inclusion time is planned to 2 years.
If your center is interested in joining the study, please contact the Principal Investigator Dr Felix Böhm, at Karolinska University Hospital in Stockholm, Sweden, or your National Coordinator. Please check under “Who are we” in the menu.
The full protocol and an executive summary is available under "Documents"